17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response.
Inhibitors of the enzyme 17alpha-hydroxylase/17,20 lyase are a new class of anti-prostate cancer agents currently undergoing preclinical and clinical development. We have previously reported the superior anticancer activity of our novel 17alpha-hydroxylase/17,20 lyase inhibitor, VN/124-1, against androgen-dependent cancer models. Here, we examined the effect of VN/124-1 on the growth of the androgen-independent cell lines PC-3 and DU-145 and found that the compound inhibits their growth in a dose-dependent manner in vitro (GI50, 7.82 micromol/L and 7.55 micromol/L, respectively). We explored the mechanism of action of VN/124-1 in PC-3 cells through microarray analysis and found that VN/124-1 up-regulated genes involved in stress response and protein metabolism, as well as down-regulated genes involved in cell cycle progression. Follow-up real-time PCR and Western blot analyses revealed that VN/124-1 induces the endoplasmic reticulum stress response resulting in down-regulation of cyclin D1 protein expression and cyclin E2 mRNA. Cell cycle analysis confirmed G1-G0 phase arrest. Measurements of intracellular calcium levels ([Ca2+]i) showed that 20 micromol/L VN/124-1 caused a release of Ca2+ from endoplasmic reticulum stores resulting in a sustained increase in [Ca2+]i. Finally, cotreatment of PC-3 cells with 5, 10, and 20 micromol/L VN/124-1 with 10 nmol/L thapsigargin revealed a synergistic relationship between the compounds in inhibiting PC-3 cell growth. Taken together, these findings show VN/124-1 is endowed with multiple anticancer properties that may contribute to its utility as a prostate cancer therapeutic.
Bruno
Robert D
RD
Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, MD 21201-1559, USA.
Gover
Tony D
TD
Burger
Angelika M
AM
Brodie
Angela M
AM
Njar
Vincent C O
VC
D000728:Androgens / Q000378:metabolism; D000730:Androstadienes / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D001562:Benzimidazoles / Q000737:chemistry / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism; D018797:Cell Cycle Proteins / Q000235:genetics / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D019938:Cyclin D1 / Q000235:genetics; D015536:Down-Regulation / Q000187:drug effects; D004357:Drug Synergism; D004721:Endoplasmic Reticulum / Q000187:drug effects / Q000235:genetics / Q000473:pathology*; D015852:Eukaryotic Initiation Factor-2 / Q000378:metabolism; D016193:G1 Phase / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D052138:Genes, Neoplasm; D008297:Male; D020411:Oligonucleotide Array Sequence Analysis; D010766:Phosphorylation / Q000187:drug effects; D011471:Prostatic Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000473:pathology*; D016192:Resting Phase, Cell Cycle / Q000187:drug effects; D013254:Steroid 17-alpha-Hydroxylase / Q000037:antagonists & inhibitors*; D019284:Thapsigargin / Q000494:pharmacology; D015854:Up-Regulation / Q000187:drug effects
D000728:Androgens; D000730:Androstadienes; D001562:Benzimidazoles; D018797:Cell Cycle Proteins; D015852:Eukaryotic Initiation Factor-2; D019938:Cyclin D1; D019284:Thapsigargin; D013254:Steroid 17-alpha-Hydroxylase; D002118:Calcium; C500627:3-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene
Oncogene. 2004 Apr 19;23(18):3180-8
15094767
FASEB J. 2005 Feb;19(2):240-2
15545299
Cancer Res. 2007 Nov 15;67(22):10631-4
18006802
Mol Cancer Ther. 2006 Mar;5(3):556-63
16546969
Cell Stress Chaperones. 2004 Mar;9(1):76-87
15270080
J Med Chem. 1995 Jun 23;38(13):2463-71
7608911
Urol Clin North Am. 1991 Feb;18(1):1-13
1899494
Nat Med. 2002 Aug;8(8):816-24
12118244
Genes Dev. 1999 May 15;13(10):1211-33
10346810
Curr Pharm Des. 1999 Mar;5(3):163-80
10066888
Physiology (Bethesda). 2007 Jun;22:193-201
17557940
J Clin Invest. 2002 Nov;110(10):1383-8
12438433
J Med Chem. 1998 Mar 12;41(6):902-12
9526564
J Med Chem. 2004 Dec 30;47(27):6716-29
15615521
J Biol Chem. 2004 Feb 13;279(7):5059-65
14617629
Mol Cell Biol. 1998 Dec;18(12):7499-509
9819435
Br J Cancer. 2008 Apr 8;98(7):1234-43
18349838
Mol Cancer Ther. 2007 Apr;6(4):1262-75
17431104
Leuk Res. 2005 Oct;29(10):1181-90
15936073
Mol Cell Biochem. 1993 Nov;127-128:255-65
7935356
Genes Dev. 1998 Apr 1;12(7):982-95
9531536
Cancer Chemother Pharmacol. 1993;31(4):259-64
8422687
Cell. 2000 May 26;101(5):451-4
10850487
Cancer Res. 2000 Jun 1;60(11):2919-25
10850438
Endocrinology. 1988 Dec;123(6):2675-82
2848682
Nat Med. 2004 Jan;10(1):33-9
14702632
J Biol Chem. 1985 Mar 25;260(6):3440-50
3838314
J Steroid Biochem Mol Biol. 1991;40(4-6):527-32
1958554
J Biomed Sci. 2003 May-Jun;10(3):313-9
12711858
Cancer Metastasis Rev. 1998-1999;17(4):361-71
10453280
J Urol. 1983 Jul;130(1):152-3
6306286
Cancer Res. 2007 Feb 1;67(3):1262-9
17283163
Mol Pharmacol. 2006 Oct;70(4):1424-34
16849592
J Urol. 1997 Apr;157(4):1204-7
9120902
J Med Chem. 2005 Apr 21;48(8):2972-84
15828836
Br J Cancer. 2004 Jun 14;90(12):2317-25
15150570
Nature. 1999 Jan 21;397(6716):271-4
9930704
Genes Dev. 1997 Jun 1;11(11):1479-92
9192874
J Biol Chem. 1997 Aug 29;272(35):21751-9
9268304
Prostate. 2007 May 1;67(6):630-7
17342748
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8280-5
9653178